8.2 (10.2) Palliation of nausea and vomiting Flashcards
What are the 3 phases of emesis
Prodrome, retching, vomiting
What acts as a centre for integration of diverse stimuli (aka vomiting centre) and where is it located?
Nucleus Tractus Solitarius (NTS) located in dorsal medulla of the brainstem
List 4 main afferent sources for the vomiting centre/NTS in the human brain and the NTs associated with them
*cerebral cortex and higher brainstem - GABA, 5HT2
*CTZ (can only initiate vomiting via the VC) - 5HT3, D, NK
*vestibular system - H1, M
*GI tract, viscera, heart and thorax (via vagus nerve) - 5HT3
List 3 main effector pathways from NTS
Cerebral cortex -> nausea
Endocrine (hypothalamus, pituitary gland) -> decrease appetite
Autonomic motor nuclei -> stomach -> vomiting
Fig. 8.2.1
List the major NTs that act on the CTZ
dopamine
serotonin 5HT3
neurokinin
List the major NTs that DIRECTLY act on the VC (NTS)
histamine
acetylcholine
serotonin (5HT3 and 5HT2)
Neurokinin 1
(No dopamine)
What are 2 dominant sites of NK 1 receptors responsible for emesis?
CTZ and NTS (both located in the medulla oblangata of brainstem)
What are the two approaches to the selection of an antiemetic for a patient with nausea? What is generally preferred and why?
Two strategies have been proposed for the management of NV:
1) Etiologic based approach
2) Empirical approach.
The Etiology approach (Table 8.2.1) - recommended as more rapid relief of nausea
- involves identifying the most likely cause of the nausea, the pathways and receptors involved
- Drugs known to inhibit those particular receptors are then chosen
You are seeing a patient in consultation for nausea. You decide to take a mechanistic approach to the selection of an antiemetic. What six steps will you take in managing the patient’s nausea?
- Identify the likely cause(s) of nausea and/or vomiting
- Identify the pathway by which each cause triggers the vomiting reflex.
- Identify the neurotransmitter receptor involved in the identified pathway.
- Choose the most potent antagonist (i.e. anti-emetic) to the receptor identified
- Choose a route of administration that ensures that the drug reaches its site of action (usually not PO)
- Titrate the dose carefully, review the patient frequently.
- Give the antiemetic regularly.
- If symptoms persist, review the likely cause(s): additional treatment may be required for an overlooked cause, or alternative treatment may be suggested by a different cause becoming apparent.
- If combining antiemetics, potential drug interactions need to be considered
List three classes of dopamine antagonists and give an example of each. Which is the most potent receptor blocker in the CTZ?
phenothiazines - prochlorperazine, methrotrimeprazine (note - broad spectrum)
butyrophenones - haloperidol - most potent receptor blocker or CTZ
benzamides - metoclopramide, domperidone
What are three side effects of low potency phenothiazines and which receptors are responsible for these side effects?
anti-dopamine - EPS
alpha 1 adrenergic receptor - hypotension, sedation
anti-histamine - dry mouth, sedation
anti muscarinic toxicities - mad as a hatter, hot as hell, red as a beat, dry as a bone, and blind as a bat.
List four examples of extrapyramidal symptoms that may occur from the use of dopamine antagonists
akathisia
acute dystonia
pseudoparkinsonism
tardive dyskinesia
What are three predominant indications for the use of 5HT3 receptor antagonists in the management of NV
chemotherapy induced NV
radiotherapy NV
post operative NV
List four common side effects of 5HT3 antagonists
Headache
dizziness
constipation
QTc prolongation
FS:
- GASH (uptodate) - GI, anxiety, sedation/dizzy, headache
- QTC
For what causes of nausea would you use the following drugs?
- corticosteroids
- cannabinoids
- benzo
- octreotide
- mirtazapine
- NK1 receptor antagonist
- corticosteroids - intracranial tumors, bowel obstruction
- cannabinoids - Chemo-Induced N/V (CINV)
- benzo - anticipatory nausea, CINV
- octreotide - malignant bowel obstruction
- mirtazapine - nausea associated with cancer (has 5HT3 activity)
- NK1 receptor antagonist - CINV